Pipeline Therapeutics to Participate in the 19th Annual Needham Virtual Healthcare Conference

Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced that the company will participate in the 19th Annual Needham Virtual Healthcare Conference, a fully virtual management access conference, taking place April 14-15.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Thursday, April 9, 2020
Information
Tags: 
Biotechnology, Pharmaceutical, Health, Neurophysiology, Neuroregeneration, Axon, Synaptopathy, Biology
Geotags: 
California, United States
⚠generated by AI ↴
Summary
Key Points: 
  • Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced that the company will participate in the 19th Annual Needham Virtual Healthcare Conference, a fully virtual management access conference, taking place April 14-15.
  • Pipeline Therapeutics is a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, including synaptogenesis, remyelination and axonal repair.
  • The companys lead product candidate, PIPE-505, is a small molecule gamma secretase inhibitor (GSI) to treat mild-to-moderate sensorineural hearing loss (SNHL) associated with cochlear synaptopathy.
  • The company also has a portfolio of programs, including PIPE-307, focused on remyelination and axonal repair, to address a range of neurological disorders, including multiple sclerosis.


Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced that the company will participate in the 19th Annual Needham Virtual Healthcare Conference, a fully virtual management access conference, taking place April 14-15.

About Pipeline Therapeutics

Pipeline Therapeutics is a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, including synaptogenesis, remyelination and axonal repair. The company’s lead product candidate, PIPE-505, is a small molecule gamma secretase inhibitor (GSI) to treat mild-to-moderate sensorineural hearing loss (SNHL) associated with cochlear synaptopathy. The company also has a portfolio of programs, including PIPE-307, focused on remyelination and axonal repair, to address a range of neurological disorders, including multiple sclerosis. For more information, please visit www.pipelinetherapeutics.com.

Copyright: 
Copyright Business Wire 2020